Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, a… Read more
Biocon Limited (BIOCON) - Total Liabilities
Latest total liabilities as of December 2025: ₹295.40 Billion INR
Based on the latest financial reports, Biocon Limited (BIOCON) has total liabilities worth ₹295.40 Billion INR as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biocon Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Biocon Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biocon Limited Competitors by Total Liabilities
The table below lists competitors of Biocon Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Firefly Aerospace Inc. Common Stock
NASDAQ:FLY
|
USA | $307.37 Million |
|
Beijing Ultrapower Software
SHE:300002
|
China | CN¥943.57 Million |
|
Steel Authority of India Limited
NSE:SAIL
|
India | ₹758.85 Billion |
|
China Nuclear Engineering Co
SHG:601611
|
China | CN¥210.05 Billion |
|
Mankind Pharma Ltd
NSE:MANKIND
|
India | ₹132.85 Billion |
|
Stella-Jones Inc
PINK:STLJF
|
USA | $1.98 Billion |
|
China Zhenhua Group Science & Technology Co Ltd
SHE:000733
|
China | CN¥3.37 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Biocon Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.13 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biocon Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biocon Limited (2004–2025)
The table below shows the annual total liabilities of Biocon Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹310.85 Billion | +0.94% |
| 2024-03-31 | ₹307.96 Billion | +4.20% |
| 2023-03-31 | ₹295.54 Billion | +170.54% |
| 2022-03-31 | ₹109.24 Billion | +9.08% |
| 2021-03-31 | ₹100.15 Billion | +41.84% |
| 2020-03-31 | ₹70.61 Billion | +28.72% |
| 2019-03-31 | ₹54.85 Billion | +26.36% |
| 2018-03-31 | ₹43.41 Billion | +3.85% |
| 2017-03-31 | ₹41.80 Billion | +1.59% |
| 2016-03-31 | ₹41.15 Billion | +40.31% |
| 2015-03-31 | ₹29.33 Billion | +11.02% |
| 2014-03-31 | ₹26.42 Billion | +59.50% |
| 2013-03-31 | ₹16.56 Billion | -0.76% |
| 2012-03-31 | ₹16.69 Billion | +12.48% |
| 2011-03-31 | ₹14.84 Billion | +29.63% |
| 2010-03-31 | ₹11.44 Billion | +13.53% |
| 2009-03-31 | ₹10.08 Billion | +67.43% |
| 2008-03-31 | ₹6.02 Billion | +18.86% |
| 2007-03-31 | ₹5.07 Billion | +27.90% |
| 2006-03-31 | ₹3.96 Billion | +13.64% |
| 2005-03-31 | ₹3.49 Billion | +56.09% |
| 2004-03-31 | ₹2.23 Billion | -- |